Galmed Pharmaceuticals Ltd
10
1
2
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
20.0%
2 terminated/withdrawn out of 10 trials
75.0%
-11.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Single and Multiple Dose Pharmacokinetics (PK) of Aramchol From an Aramchol Meglumine Tablet
Role: lead
Comparing The PK Of Aramchol Meglumine Granules To Aramchol Free Acid Tablets
Role: lead
A Study Evaluating the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Primary Sclerosing Cholangitis
Role: lead
An Open-Label, Two-Part Study Designed to Assess the Absolute Bioavailability and Mass Balance of Aramchol
Role: lead
A First-in-Human Study of Single and Multiple Doses of Amilo-5MER in Healthy Subjects
Role: lead
Study of Potential for Drug Interactions Mediated by CYP3A4 Inhibition With Aramchol in Healthy Volunteers
Role: lead
Comparison of Aramchol Concentrations With Once or Twice Daily Dosing
Role: lead
Pharmacokinetics of Single and Multiple Escalating Doses of Aramchol Administered Under Fed Conditions in Healthy Chinese Volunteers
Role: lead
Medical Dissolution of Cholesterol Gallstones Using Oral Aramchol - A Proof of Concept Phase IIa Study
Role: lead
Pharmacokinetics of Single and Multiple Escalating Doses of Aramchol and Food Effect in Healthy Volunteers
Role: lead
All 10 trials loaded